VIGOR Study Design

• Large, prospective, randomized controlled study (8,000 patients, median f.u. 9 months)

• Treatment: Rofecoxib 50 mg q.d. Naproxen 500 mg b.i.d.

• Population: RA

Low dose ASA not allowed

• Endpoints: Safety (GI and general safety)

  Not designed to address efficacy
  
  

Previous slide

Next slide

Back to first slide

View graphic version